NVCR Live signals | Maximize Profits with Getagraph.com

SELL 105678 min ago

@ $15.54

Issued: 14 Feb 2024 @ 12:55

Return: -18.68%

Previous signal: Feb 14 - 12:01

Previous signal: Buy

Return: 1.34 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	761 328
Average Volume	1.28M
Market Cap	1.36B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.420 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.48
ATR14	$0.0120 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Groenhuysen Wilhelmus Cm	Sell	2 107	Ordinary Shares
2024-03-04	Groenhuysen Wilhelmus Cm	Sell	1 217	Ordinary Shares
2024-03-01	Leonard Frank X	Sell	1 679	Ordinary Shares
2024-03-04	Leonard Frank X	Sell	840	Ordinary Shares
2024-02-27	Cordova Ashley	Buy	102 249	Ordinary Shares

INSIDER POWER
77.63
Last 92 transactions
Buy: 1 705 026 \| Sell: 238 995

Volume Correlation

Long: 0.39 (neutral)

Short: 0.88 (strong)

Signal:(68.11) Same movement expected

Novocure Ltd Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Novocure Ltd Correlation - Currency/Commodity

-0.08
( neutral )

0.00
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.01
( neutral )

Novocure Ltd Financials

Annual	2023
Revenue:	$509.34M
Gross Profit:	$381.06M (74.81 %)
EPS:	$-1.950

FY	2023
Revenue:	$509.34M
Gross Profit:	$381.06M (74.81 %)
EPS:	$-1.950

FY	2022
Revenue:	$537.84M
Gross Profit:	$422.97M (78.64 %)
EPS:	$-0.880

FY	2021
Revenue:	$535.03M
Gross Profit:	$420.15M (78.53 %)
EPS:	$-0.563

Financial Reports:

No articles found.

Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Realtime updates for Novocure Ltd [NVCR]

Upcoming Earnings Alert